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and a Patient Generated Subjective Global Assessment (PG-SGA)
is used to assess overall nutritional risk. The RD assesses the
macro- and micronutrient adequacy and tolerance of each patient’s
diet. Nutrition standards of care include counseling by the RD on
individual calorie, protein, and vitamin/mineral requirements and
how best to achieve these goals. At our institution three RD’s
provide care in the GVHD clinic. In order to standardize care
across the RD’s and to facilitate communication with the interdis-
ciplinary team, nutrition algorithms were developed. The RD’s
reviewed each of the most common types of GVHD with nutri-
tional implications. They were divided into ﬁve main focuses: 1)
Upper GI (oral/esophageal) GVHD; 2) Lower GI and Liver
GVHD (large volume diarrhea); 3) Anorexia/Failure to Thrive; 4)
Skin GVHD; 5) High Dose Steroid Use. The algorithms are a
series of interventions organized based on such factors as patient’s
ability to eat, adequacy of diet, weight loss, and GI symptoms.
Initial interventions include diet education along with nutritional
and vitamin/mineral supplementation. If these are unsuccessful,
pharmacological interventions and nutrition support via either an
enteral or parenteral route are instituted. Current plans include a
research protocol to evaluate preservation of lean body mass and
improvement in quality of life when nutrition algorithms are fol-
lowed in chronic GVHD patients.
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A MULTI-INSTITUTIONAL STUDY OF EXTRACORPOREAL PHOTO-
PHORESIS (ECP) WITH UVADEX FOR THE PREVENTION OF ACUTE
GRAFT VS. HOST DISEASE (AGVHD) IN PATIENTS (PTS) UNDERGOING
ALLOGENEIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTS
(ALLO-HPCT) WITH MYELOABLATIVE CONDITIONING
Abhyankar, S.1, Bolwell, B.J.2, Shaughnessy, P.J.3, van Besien, K.4,
Ilhan, O.5, Machado, A.6, Dodds, A.7, Grigg, A.8, Prince, H.M.9,
Mistrik, M.10, Gruben, D.11, Thienel, U.11 1. Kansas City Cancer
Center, Kansas City, MO; 2. The Cleveland Clinic Foundation, Cleve-
land, OH; 3. Texas Transplant Institute, San Antonio, TX; 4. Univer-
sity of Chicago, Chicago, IL; 5. Ankara University Medical School,
Ankara, Turkey; 6. Instituto Portugues de Oncologia de Francisco Gentil,
Lisbon, Portugal; 7. St Vincent’s Hospital, Sydney, Australia; 8. Royal
Melbourne Hospital, Melbourne, Australia; 9. Peter MacCallum Cancer
Institute, East, Melbourne, Australia; 10. Klinika Hematologie a Trans-
fuziologie, Bratislavia, Slovakia (Slovak Republic); 11.Clinical Develop-
ment, Therakos, Inc, Exton, PA; 12. The Photopheresis Study Group,.
GvHD remains a major cause of morbidity and mortality after an
allo-HPCT, and ECP has been shown in numerous studies to be
effective in its treatment. ECP has also been used in the prevention
of GvHD in a novel non-myeloablative preparative regimen for
allo-HPCT (Foss, BBMT 9:96, 2003). The incidence of aGvHD
was substantially reduced in this study, possibly due to the effect of
ECP on host dendritic cells, causing alteration in allo-antigen
presentation and reduced donor T-cell activation. We report here
the preliminary results of a multi-institutional phase II study uti-
lizing ECP with Uvadex® in a myeloablative regimen of allo-
HPCT. Treatment with ECP was given on any two days from Day
–10 to –6, followed by cyclophosphamide 60mg/kg for 2 days and
TBI 1200 cGy over three days. Pts. received cyclosporine (CSA)
3-5mg/kg iv from Day –1 (and switched later to PO), to keep levels
between 200-600 ng/ml, and methotrexate 10mg/m2 on Days 1,3,6
and 11 for matched unrelated donors (MUD) and one antigen
mismatched related donors, and 10mg/m2 on Day 1 and 5mg/m2
on Days 3,6 and 11 in matched related donors (MRD), as GvHD
prophylaxis. CSA was continued until Day 100 and then tapered.
Data is available on 34 of 50 enrolled pts. Nineteen pts. are male
and the median age is 37 (range 20 –58). Diagnosis leading to
HPCT includes acute leukemia and myelodysplasia (n  21),
chronic leukemia (n  9), lymphoma (n  3) and other (n  1).
Eighteen pts. received bone marrow (BM) and 16 peripheral blood
(PB) HSCT. Nineteen pts. received matched unrelated or mis-
matched related grafts and 15 matched related. Median time to
engraftment was 20 days for BM and 15 days for PB. ECP was well
tolerated in 33 pts. with one pt. having mild reversible hypoten-
sion. ECP was not discontinued on any pt. At a median follow up
of 85 days (range 5 to 295), acute GvHDGrade II–IV developed in
11 (35.5%) pts. (6 with BM and 5 with PB; 4 with MRD HPCT
and 7 with MUD HPCT). Three pts.died (all MUD HPCT) at a
median of 47 days from HPCT, two from aGvHD (Grades III and
IV), and one from multi-organ failure. 31 pts. are alive while 3 have
relapsed (2 with ALL and 1 NHL). This preliminary analysis
shows that ECP can safely be administered to pts. undergoing
myeloablative allo-HPCT. Further follow up is ongoing to assess
acute and chronic GvHD rates, relapse and transplant related
mortality. Pre and post–ECP lab data on T cell subsets, dendritic
cells and NK cells will also be evaluated.
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RISK FACTORS FOR SYNGENEIC GRAFT-VERSUS-HOST DISEASE IN
ADULT HEMATOPOIETIC STEM CELL TRANSPLANTS
Adams, K.M.1,2, Holmberg, L.A.1,2, Leisenring, W.1, Guthrie, K.A.1,
Tylee, T.S.2, McDonald, G.B.1,2, Bensinger, W.I.1,2, Nelson, J.L.1,2 1.
Fred Hutchinson Cancer Research Center, Seattle, WA; 2. University of
Washington, Seattle, WA.
Cutaneous, hepatic and gastrointestinal graft-versus-host disease
(GVHD) has been described after both syngeneic and autologous
stem cell transplants. The recent ﬁnding of male DNA in female
donor apheresis products and associations between parous donors
and allogeneic GVHD raise the question of whether persistent
pregnancy-derived fetal microchimerism in donors or recipients
could contribute to the development of sGVHD. Our objective
was to identify the incidence, morbidity, and risk factors for syn-
geneic GVHD (sGVHD) following hematopoietic stem cell trans-
plantation (HSCT) with analysis focused on pregnancy history of
the donor/recipient as potential risk factors. We retrospectively
reviewed the transplant outcomes of 119 adults undergoing syn-
geneic HSCT at our center between 1980 and 2002. We required
diagnostic histological ﬁndings on a biopsy of the skin, intestinal
tract, or liver for the diagnosis of sGVHD. Among 119 syngeneic
transplants, 21 patients had biopsy-proven sGVHD for a preva-
lence of 18%. The median time to developing sGVHDwas 39 days
(range 20-79). In 6 cases, biopsies conﬁrmed multi-organ involve-
ment; sGVHD was the ofﬁcial cause of death in one case. sGVHD
developed in 24% of the women and 13% of the men. A signiﬁ-
cantly higher frequency of sGVHD occurred in the context of a
parous donor (p  0.03, parous donor 11/34, 32%; nulliparous
donor 1/11, 9%; male donor 9/70, 13%) or parous recipient (p 
0.02, parous recipient 11/35, 31%; nulliparous recipient 1/14, 7%;
male recipient 9/70, 13%). Of 26 twin pairs with a parous donor
and parous recipient, 10 (38%) women developed sGVHD versus
no cases in 5 women with a nulliparous donor and recipient (p 
0.10). Other factors signiﬁcantly associated with sGVHD on uni-
variable analysis include older age (p  0.004), Busulfan/Melpha-
lan/Thiotepa conditioning (p  0.002), interleukin-2 therapy (p 
0.017), HLA-A26 type (p  0.02), and more recent transplant year
(p  0.004). In a Cox regression model based on suggestive uni-
variable predictors, only recipient parity and more recent trans-
plant year remained signiﬁcantly associated with sGVHD. The
ﬁnding of recipient parity as a risk factor for sGVHD may support
a role for fetal microchimerism in sGVHD.
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IMMUNOLOGICAL EFFECTS OF DONOR LYMPHOCYTE INFUSION IN
PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA RELAPSING AF-
TER ALLOGENEIC BONE MARROW TRANSPLANTATION
Voltarelli, J.1, Palma, P.1, Morais, F.1, Castro, F.2 1. Centro Regi2.
2Faculdade de Ciencias Farmaceuticas USP, Ribeirao Preto, State of Sao
Paulo, Brazil.
Donor lymphocyte infusion (DLI) is a very efﬁcient therapy for
relapse of chronic myelogenous leukemia in chronic phase (CP-
CML) after allogeneic bone marrow transplantation (BMT). Infu-
sion of allogeneic lymphocytes induces a graft-versus-leukemia
(GVL) effect which produces long term remission in most patients.
However, immunological mechanisms involved in this reaction are
poorly understood. We studied several immunological markers and
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functions pre-infusion and at different points post-DLI (D11,
30, 60, 90, 360) in ﬁve patients with CP-CML who re-
lapsed after allogeneic BMT. In three patients who achieved he-
matological and cytogenetic remission after DLI we observed a
statistically signiﬁcant increase in the percentage and absolute
numbers of CD8 and CD56 lymphocytes, in the percentage of
activation markers on T and NK cells (CD3/DR, CD3/CD25 and
CD56/DR), of lymphocytes producing IL-2 or interferon-gamma,
in NK activity and in non-stimulated lymphocyte proliferation.
These changes were not observed in two patients who did not
achieve complete remission after DLI. The percentage of apopto-
tic markers (Fas, FasL and Bcl-2) on lymphocytes or CD34 cells
did not change after DLI. Taken together, these preliminary re-
sults suggest that the therapeutic effect of DLI on CP-CML is
mediated by classical cytotoxic and proliferative events involving T
and NK lymphocytes.
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OVERLAPPING IMMUNE RESPONSES IN DONOR LYMPHOCYTE INFU-
SION (DLI)-ASSOCIATED GRAFT-VS-HOST DISEASE
Hess, A.D., Miura, Y., Bright, E.C., Thoburn, C.J., Vogelsang, G.B.
The Johns Hopkins University, Baltimore, MD.
Infusion of donor lymphocytes (DLI) is a viable approach to
eliminate residual tumor cells following non-myeloablative stem
cell transplantation (SCT). Following DLI, severe GVHD often
develops with a rapid onset and can include elements of both acute
and chronic GVHD. Interestingly, type 1 and 2 cytokines play a
major role in acute and chronic GVHD, respectively, To further
explore the pathophysiology of DLI-associated GVHD, IL-10 and
gamma interferon (IFN) cytokine proﬁles were assessed in periph-
eral blood lymphocytes (PBL) and skin biopsies from patients with
GVHD after myeloablative SCT and after Donor Lymphocyte
Infusion (DLI) following non-myeloablative SCT. PBL and skin
were analyzed for IL-10 and IFN mRNA transcripts by real-time
quantitative RT-PCR(Table 1). Patients with SCT-GVHD exhib-
ited higher levels of IFN	 mRNA transcripts (compared to tran-
scripts for IL-10) in the skin with the IL-10/IFN ratio less than 1.
Interestingly, the levels of cytokine message in the skin were much
greater than the levels detected in PBL, ﬁndings consistent with
the enrichment of activated T cells in the target tissue. Compar-
atively, patients with DLI-GVHD had a greater proportion of
IL-10 mRNA transcripts in the target tissue with IL-10/IFN	
ratios 5. The dominance of IL-10 was similar to the observations
in autologous GVHD where IL-10 mRNA levels were 6-fold
higher in patients with clinical evidence of disease. The results
suggest that there are distinct patterns of cytokine expression in
patients with DLI-GVHD that may reﬂect Th2-drived mecha-
nisms that overlap inthe acute phase of GVHD. Consistent with
this hypothesis is T cell receptor V spectratype analysis of the
target tissue. Although initial analysis indicates a broad spectrum of
T cells inﬁltrating the target tissue, subsets of T cells expressing a
few V T cell receptor genes persisted in both acute and chronic
phases of GVHD. Evaluation of the cytokine proﬁle within the
tissue provides important insights into the pathogenesis of DLI-
GVHD.
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ALLOGENEIC MEMORY RESPONSE CONTRIBUTES TO THE PERSIS-
TENCE OF ALLORECTIVE T CELLS FOR MEDIATING GRAFT-VERSUS-
HOST DISEASE
Zhang, Y., Jeo, G., Zhu, J., Emerson, S.G. Departments of Medicine,
Pediatrics, University of Pennsylvania School of Medicine, Philadelphia,
PA.
GVHD evolves over weeks to months following allogeneic bone
marrow transplantation (allo-BMT). While persistent alloreactive
T cells in vivo are believed to be essential for GVHD development,
the relative role of effector versus memory T cells in sustaining
tissue injuries remains unknown. Using a major histocompatibility
complex-identical minor antigen-mismatched mouse model, we
now report that infusion of C3H.SW CD8 T cells into B6 mice
induces both typical primary and memory-like immune responses
in recipients. We found that B6 mice receiving C3H.SW CD8 T
cells developed clinical sign of GVHD by day 21 following allo-
BMT and about 60% of them died by day 55 due to GVHD. In
parallel, alloreactive CD8 T cells secreting IFN-g peaked in the
liver of B6 mouse receiving C3H.SW CD8 T cells by day 14
(0.520.048X105), declined by day 28 (0.0550.031X105), and
increased again by day 42 (0.2880.012X105) after transplanta-
tion. A similar biphasic pattern of alloreactive CD8 T cell expan-
sion was also observed in the spleens of these B6 mice. The decline
in alloreactive T cells was accompanied with increased Annexin
V-positive donor CD8 T cells in the spleens (10.13.1% at day 21
vs. 4.53.0% at day 14) and livers (9.02.3% at day 21 vs.
3.71.2% at day 14) of these B6 recipients. Interestingly, donor
CD8 T cells recovered from B6 mice receiving C3H.SW CD8 T
cells at days 42 after allo-BMT expressed low levels of CD25 but
high levels of CD44 and CD122, and contained at least two distinct
subsets:CD62Llo and CD62Lhi CD8 T cells. Both the CD62Llo
and CD62Lhi CD8 T cells were able to rapidly produce high levels
of IFN-g ex vivo, corresponding to effector memory and central
memory CD8 T cells, respectively. When each population was
separately transferred along with C3H.SW T cell-depleted BM
into irradiated secondary B6 mice, both CD62Lhi and CD62Llo
CD8 T cells survived and vigorously expanded in the secondary
recipients. As the result, 70% of these secondary B6 mice died of
GVHD by day 35. Notably, as few as 0.075X106 of CD62Lhi CD8
central memory T cells recovered from primary B6 mice with
GVHD at days 42 after allo-BMT were sufﬁcient to induce lethal
GVHD in 67.5% B6 mice. In comparison, administration of
0.5X106 C3H.SW CD44loCD62Lhi naı¨ve CD8 T cells only in-
duced lethal GVHD in 30% of B6 mice. These ﬁndings indicate
that allogeneic memory T cell responses may be responsible for the
persistence of alloreactive T cells mediating tissue injuries.
Table. Cytokine mRNA Transcripts in PBLs and Target Tissue
Sample
No.
Sample
Source IL-10 IFN
IL-10/
IFNRatio
0 Controls
(n  10)
PBL 0.66 1.41 0.5
1 DLI PBL 0.3 14.8 0.02
Skin 2.8 0.2 14.0
2 DLI PBL 9.8 29.6 0.3
Skin 44.8 3.1 14.5
3 DLI PBL 8.5 0.9 9.4
Skin 25.8 4.9 5.3
4 DLI PBL 167.5 1 167.0
Skin 12.9 1 13.0
5 MHC Matched—
Related
PBL 3.9 0.7 5.6
Skin 103.1 3571.0 0.03
6 MHC Mismatch—
Related
PBL 7.9 19.5 0.4
Skin 63.3 78.1 0.8
7 MHC Matched—
Unrelated
PBL 126.7 12.9 9.8
Skin 2.4 1887.0 0.001
8 MHC Matched—
Unrelated
PBL 51.5 4.6 11.0
Skin 3.9 15.9 0.24
9 MHC Matched—
Related
PBL 29.6 27.6 1.1
Skin 51.5 136.0 0.38
Relative transcripts normalized against the housekeeping gene GAPDH (1/(CT cyto-
kine-CT GAPDH)2  104.
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